Tags

Type your tag names separated by a space and hit enter

Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Pharmacotherapy. 2005 Mar; 25(3):335-44.P

Abstract

STUDY OBJECTIVES

To determine the effects of atorvastatin on low-density lipoprotein cholesterol (LDL) particle size and C-reactive protein (CRP) concentrations in patients undergoing long-term hemodialysis. Another objective was to compare the effects of atorvastatin on lipoprotein profiles as determined by direct versus indirect assessment of lipoprotein composition.

DESIGN

Randomized, parallel-group substudy.

SETTING

Two university-affiliated outpatient hemodialysis centers.

PATIENTS

Nineteen patients with LDL levels above 100 mg/dl and with at least two cardiovascular risk factors.

INTERVENTION

Patients were randomized in a 1:1 ratio to atorvastatin 10 mg/day or no treatment (control) for 20 weeks.

MEASUREMENTS AND MAIN RESULTS

We compared the differences between LDL particle size and CRP levels at baseline and 20 weeks in the atorvastatin versus control groups. Baseline demographic characteristics were similar between the two groups. Atorvastatin therapy was associated with no change in mean LDL particle size (p=0.23) and with a 90% decrease in mean CRP level (p=0.52). When evaluated by standard chemical analysis, atorvastatin therapy reduced total cholesterol levels by 29% (p=0.025) and resulted in nonsignificant reductions in LDL, high-density lipoprotein cholesterol, and triglyceride levels. Treatment with atorvastatin was not associated with significant changes in lipoprotein profile as determined by nuclear magnetic resonance (NMR) spectroscopy.

CONCLUSION

Treatment with atorvastatin did not affect LDL particle size but was associated with a sizable, yet nonsignificant, reduction in CRP concentrations. The drug had variable effects on lipoprotein concentrations as determined by chemical and NMR analytical methods. A larger study is necessary to provide definitive information on the effects of atorvastatin on LDL phenotype and CRP in patients with kidney disease.

Authors+Show Affiliations

Department of Pharmacotherapy, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15843280

Citation

Dornbrook-Lavender, Kimberly A., et al. "Effects of Atorvastatin On Low-density Lipoprotein Cholesterol Phenotype and C-reactive Protein Levels in Patients Undergoing Long-term Dialysis." Pharmacotherapy, vol. 25, no. 3, 2005, pp. 335-44.
Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, et al. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy. 2005;25(3):335-44.
Dornbrook-Lavender, K. A., Joy, M. S., Denu-Ciocca, C. J., Chin, H., Hogan, S. L., & Pieper, J. A. (2005). Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy, 25(3), 335-44.
Dornbrook-Lavender KA, et al. Effects of Atorvastatin On Low-density Lipoprotein Cholesterol Phenotype and C-reactive Protein Levels in Patients Undergoing Long-term Dialysis. Pharmacotherapy. 2005;25(3):335-44. PubMed PMID: 15843280.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. AU - Dornbrook-Lavender,Kimberly A, AU - Joy,Melanie S, AU - Denu-Ciocca,Cynthia J, AU - Chin,Hyunsook, AU - Hogan,Susan L, AU - Pieper,John A, PY - 2005/4/22/pubmed PY - 2005/5/19/medline PY - 2005/4/22/entrez SP - 335 EP - 44 JF - Pharmacotherapy JO - Pharmacotherapy VL - 25 IS - 3 N2 - STUDY OBJECTIVES: To determine the effects of atorvastatin on low-density lipoprotein cholesterol (LDL) particle size and C-reactive protein (CRP) concentrations in patients undergoing long-term hemodialysis. Another objective was to compare the effects of atorvastatin on lipoprotein profiles as determined by direct versus indirect assessment of lipoprotein composition. DESIGN: Randomized, parallel-group substudy. SETTING: Two university-affiliated outpatient hemodialysis centers. PATIENTS: Nineteen patients with LDL levels above 100 mg/dl and with at least two cardiovascular risk factors. INTERVENTION: Patients were randomized in a 1:1 ratio to atorvastatin 10 mg/day or no treatment (control) for 20 weeks. MEASUREMENTS AND MAIN RESULTS: We compared the differences between LDL particle size and CRP levels at baseline and 20 weeks in the atorvastatin versus control groups. Baseline demographic characteristics were similar between the two groups. Atorvastatin therapy was associated with no change in mean LDL particle size (p=0.23) and with a 90% decrease in mean CRP level (p=0.52). When evaluated by standard chemical analysis, atorvastatin therapy reduced total cholesterol levels by 29% (p=0.025) and resulted in nonsignificant reductions in LDL, high-density lipoprotein cholesterol, and triglyceride levels. Treatment with atorvastatin was not associated with significant changes in lipoprotein profile as determined by nuclear magnetic resonance (NMR) spectroscopy. CONCLUSION: Treatment with atorvastatin did not affect LDL particle size but was associated with a sizable, yet nonsignificant, reduction in CRP concentrations. The drug had variable effects on lipoprotein concentrations as determined by chemical and NMR analytical methods. A larger study is necessary to provide definitive information on the effects of atorvastatin on LDL phenotype and CRP in patients with kidney disease. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/15843280/Effects_of_atorvastatin_on_low_density_lipoprotein_cholesterol_phenotype_and_C_reactive_protein_levels_in_patients_undergoing_long_term_dialysis_ L2 - https://doi.org/10.1592/phco.25.3.335.61599 DB - PRIME DP - Unbound Medicine ER -